We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.
- Authors
Corominas, Josep; Sapena, Victor; Sanduzzi-Zamparelli, Marco; Millán, Cristina; Samper, Esther; Llarch, Neus; Iserte, Gemma; Torres, Ferràn; Da Fonseca, Leonardo G.; Muñoz-Martínez, Sergio; Forner, Alejandro; Bruix, Jordi; Boix, Loreto; Reig, María; Avila, Matias A.
- Abstract
Simple Summary: Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1+ cells express activation markers, T DNAM-1+ cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.
- Subjects
LYMPHOCYTE metabolism; CYTOKINES; DRUG side effects; FLOW cytometry; HEPATOCELLULAR carcinoma; IMMUNE system; IMMUNOSUPPRESSION; IMMUNOTHERAPY; KILLER cells; REGRESSION analysis; RISK assessment; SKIN diseases; T cells; STATISTICAL models; MONONUCLEAR leukocytes; SORAFENIB; IMMUNE checkpoint inhibitors; DISEASE risk factors
- Publication
Cancers, 2021, Vol 13, Issue 3, p426
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13030426